Rosenblatt reiterates Marvell stock Buy rating on M&A strategy
Rosenblatt reiterated a Buy rating and $300 price target for Marvell (MRVL), citing its M&A strategy and potential $100B acquisition. Lumentum (LITE) shares rose 0.6% amid talks of a deal, with Rosenblatt raising its target to $1,300. Marvell's stock has surged 360% in a year, but is seen as overvalued.
How this was made
The 30-second read
Why it matters
The coverage upgrades both stocks, suggesting near‑term buying opportunities tied to the acquisition narrative.
Market read
Analyst upgrades and a potential $100B acquisition create immediate market interest in both MRVL and LITE.
What to watch
China SAMR review timeline and integration risks could delay or diminish the expected synergies.
Background
Analyst firm Rosenblatt emphasizes Marvell's M&A strategy and its potential to create scale advantages, while Lumentum's capital‑intensive model contrasts with Marvell's fabless approach.
Ticker impact
Rosenblatt reiterated a Buy rating and raised the price target for Marvell Technology, citing advanced acquisition talks with Lumentum and a potential $100B deal.
likely upward pressure as investors price in acquisition premium and higher target.
Analyst upgrade with a $300 target and a sizable deal prospect creates immediate buying interest.
Lumentum is reported to be in advanced talks to be acquired by Marvell, prompting a raised price target to $1,300.
potential upside as market anticipates a buyout premium.
Buy rating and higher target reflect expected acquisition premium.
Market effects
The semiconductor sector may see broader valuation lifts as large-scale M&A activity signals consolidation benefits.
U.S. tech stocks could gain momentum, especially fabless peers.
Potential cross-border regulatory scrutiny (U.S. and China) adds risk but also highlights global supply-chain dynamics.
Counterpoint
If regulatory approvals stall, the deal could fall apart, causing a sell‑off in both stocks.
Key entities
- Analyst FirmRosenblatt
Provides Buy rating and price targets for MRVL and LITE.
- Analyst FirmPiper Sandler
Maintains Overweight rating on MRVL.



